How does FDA regulate ingredient disclosure and marketing claims for dietary supplements sold as sexual‑health aids?

1. How FDA classifies sexual‑health supplements and why that matters

Under the Dietary Supplement Health and Education Act (DSHEA) dietary supplements are treated as a category of foods, not drugs, which means they are not subject to the premarket safety-and‑efficacy approval process required for pharmaceuticals; manufacturers are responsible for ensuring safety and truthful labeling before marketing ^{[1] [3]}. That legal classification is the hinge: if a product is marketed to “diagnose, treat, cure, or prevent” disease it is a drug and would require FDA drug approval, but if it merely supports a structure or function (for example, “supports sexual stamina”) it may remain a supplement under FDA rules ^{[6] [2]}.

2. Ingredient disclosure on labels: what must appear

Supplement manufacturers must list ingredients on a Supplement Facts panel and follow labeling regulations, and facilities that manufacture supplements must register with FDA, creating basic transparency requirements that apply to sexual‑health products too ^{[1] [7]}. For new dietary ingredients—those not marketed as supplements before October 15, 1994—manufacturers must submit safety information to FDA before marketing, whereas “old” ingredients have no premarket safety submission requirement, leaving a regulatory gap for many sexually marketed products ^{[3] [8]}.

3. Marketing claims: permitted categories and required disclaimers

Label claims are divided into health claims, nutrient content claims, and structure/function claims; supplements cannot claim to diagnose, treat, cure, or prevent disease and structure/function claims carry mandatory FDA disclaimers such as “This statement has not been evaluated by the FDA” and require a 30‑day notification to FDA after first marketing ^{[9] [3]}. Because the line between a permissible structure/function claim and an impermissible drug claim can be blurry, companies often use vague language like “supports performance” to avoid triggering drug‑claim enforcement ^{[6] [2]}.

4. Pre‑market obligations and the new dietary ingredient rule

Manufacturers introducing a new dietary ingredient must notify FDA with evidence of reasonable expectation of safe use; for ingredients sold before 1994 no such premarket proof is required, which means many products can reach consumers without FDA safety review unless the agency has reason to act ^{[3] [8]}. FDA does not pre‑approve supplement labels or marketing in most cases, which shifts the regulatory model toward industry self‑certification and postmarket surveillance ^{[2] [1]}.

5. Enforcement, postmarket action, and the FTC partnership

FDA has authority to act against adulterated or misbranded supplements after they reach the market, using inspections, warning letters, recalls, and import refusals, but limited resources and reliance on adverse event reporting constrain preemptive action ^{[1] [2] [10]}. Advertising claims online and off are reviewed principally by the FTC, which requires substantiation and can pursue deceptive advertising even when FDA’s labeling jurisdiction applies; the agencies coordinate under a liaison agreement to close enforcement gaps ^{[4] [5]}.

6. The sexual‑health marketplace in practice: risks and real examples

Sexual‑health supplements illustrate regulatory limits: FDA has warned platforms and issued alerts about products adulterated with prescription drugs (e.g., PDE5 inhibitors) or making drug‑level claims that place them outside supplement rules, and investigative reporting shows many supplements test positive for hidden prescription ingredients because FDA does not routinely verify label contents before sale ^{[11] [12]}. Critics and public‑health researchers point to weak postmarket surveillance, consumer confusion over “natural” claims, and the challenge of policing online advertising as persistent enforcement problems ^{[10] [12]}.